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Abstract Correlation of the thickness of the left ventric-
ular posterior wall (LVPWd) with various parameters,
including age, gender, weight and height, was investi-
gated in this study using regression models. Multicenter
derived database comprised over 4,000 healthy individ-
uals. The developed models were further utilized in the
in vitro–in vivo (IVIV) translation of the drug cardiac
safety data with use of the mathematical model of
human cardiomyocytes operating at the virtual healthy
population level. LVPWd was assumed to be equivalent
to the length of one-dimensional string of virtual cardiomyo-
cyte cells which was presented, as other physiological factors,
to be a parameter influencing the simulated pseudo-ECG
(pseudoelectrocardiogram), QTcF and ΔQTcF, both native
and modified by exemplar drug (disopyramide) after IKr cur-
rent disruption. Simulation results support positive correlation
between the LVPWd and QTcF/ΔQTc. Developed models
allow more detailed description of the virtual population and
thus inter-individual variability influence on the drug cardiac
safety.
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Introduction
Echocardiography has become one of the dominant cardiac
imaging techniques as it has good temporal and spatial reso-
lution, and it is widely available given its low costs compared
to other imaging modalities. This imaging technique is also
supported by the recommendations published under the aus-
pices of two major scientific cardiological societies — the
American Society of Echocardiography and the European
Association of Echocardiography [1]. Echocardiography al-
lows a detailed evaluation of the structure and function of the
heart, assessment of the function of the heart valves as well as
evaluation of potential congenital and acquired heart diseases
[2]. There are many parameters that are routinely assessed by
echocardiography, e.g., wall thicknesses, ventricular dimen-
sions, volumes, masses and ventricular function [3, 4]. In
particular, measurements of the left ventricular structure and
function are widely utilized in, e.g., daily routine as well as
intensive and postoperative care.
There has been only a handful of studies investigating the
effect of different demographic and physiological parameters
on the left ventricular posterior wall thickness (LVPWd) in
healthy adults. The fact that they were written in 1990s can
potentially leads to concerns regarding their consistency with
the best current clinical practice, both in terms of clinical
guidelines and accuracy of measurement equipment and mea-
surement technique applied. Sjögren provides a linear regres-
sion model correlating the LVPWd with age, separately for
males and females. This study, performed in a group of
healthy individuals (58 women and 42 men, aged 18–61
years), was based on echocardiographic measurements [5].
According to Sjögren, the mean LVPWd can be approximated
using the following two equations: 0.055 × age + 5.95 (equa-
tion for males), 0.096 × age + 3.83 (equation for females). The
mean free heart wall thickness was investigated by Henry and
colleagues [6]. Their study group consisted of 136 healthy
subjects (78 men and 58 women, aged 20–97 years), but the
sex of the subjects was not included in their regression
models. According to Henry, the mean free left ventricular
wall thickness can be approximated with similar accuracy
using any of the following two equations: 5.56 × body surface
area (BSA)0.5 + 0.03 × age + 1.1, 1.92 × weight0.32+0.03 ×
age + 1.1. However, Henry’s model lacks a clear definition of
the area of the ventricular wall used for the measurements, i.e.,
non-specific free wall thickness is mentioned rather than
posterior wall thickness. Kitzman and colleagues investigated
the age-, sex- and BSA-related differences in human adult
(20–99 years old) hearts based on autopsy specimens [7]. The
authors found no significant correlations between any of the
predictors and the left wall thickness in a group of 765 healthy
adults. In this study, however, the analyzed variable was not
exactly the LVPWd but average wall thickness measured at
various sites of the left ventricle. There were also LVPWd
models developed for pediatric populations, but since they are
out of the scope of the current study, we will only mention the
Carceller and colleagues study [8]. They developed a model
correlating BSA with the LVPWd, based on a group of 69
healthy individuals aged 10–20 years.
Drug-induced cardiotoxicity, with pro-arrhythmic activity
as the leading one, remains a clinical problem and novel
methods of early assessment of this phenomenon are intensely
discussed [9, 10]. Current pre-clinical approaches are based on
in vivo animal studies (dog as a leading species) and in vitro
studies assessing IKr current inhibition carried out with the use
of human ion channels expressed heterologously in various
cells [11]. Modifications of these approaches have recently
been proposed to account for more currents analysis and more
thorough data integration, due to a likely high level of false
positive signals [12]. Hence, mathematical models integrating
in vitro data are likely to become an important element of the
new paradigm [37]. These biophysically detailed mathemati-
cal models (BDMM) describe the electrophysiology of human
left ventricular cardiomyocytes. All of them are based on the
so-called Hodgkin–Huxley paradigm describing how action
potential is propagated in excitable cells [13]. In principle, it is
a set of differential equations describing ions flow through the
ion channels and pumps with relation to the external excitation
and cell capacitance. In BDMMs, the heart wall is assumed to
be equivalent to the one-dimensional string of virtual cardio-
myocyte cells, and the heart wall thickness is assumed to be
equivalent to the length of the string of virtual cells [14–16].
To that end, it is of great interest to investigate whether the
LVPWd is a relevant element of the BDMM, apart from other
parameters describing physiological factors, discussed previ-
ously in several studies [17–19]. Utilization of system infor-
mation (human physiology data) could allow for the intra- and
inter-individual variability assessment [38].
This study serves two strongly interconnected goals: (1) to
develop a regression model describing the effect of age, sex,
and BSA on the distribution of the LVPWd in healthy adults
and (2) to transfer these findings on a biophysically detailed
mathematical model describing the electrophysiology of the
human left ventricular cardiomyocytes.
Materials and Methods
Clinical Data Characteristics
Clinical data were collected retrospectively in Switzerland and
Poland. The Swiss data collection was carried out at the
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University Hospital Zurich (UHZ; N=4,472). Echocardiogra-
phy studies were performed between 1990 and 2011 (95% of
data after 2001). Detailed information regarding data collec-
tion has been previously published [20]. The Polish data
collection was carried out by the Department of Cardiology
and Internal Diseases of the Military Institute of Medicine
(Warsaw), the First Department of Cardiology, Interventional
Electrocardiology and Hypertension, University Hospital
(Krakow), the Department of Cardiac and Vascular Diseases
at the John Paul II Hospital (Krakow) and the Eskulap Med-
ical Center (Tarnow). Echocardiography studies were per-
formed in 2002 (N=36) and between 2008 and 2013 (N=
281).
The inclusion criteria were as follows: (1) LVPWd in a
physiological range 6–11 mm (range according to the current
clinical recommendations), (2) lack of known hypertension
and other cardiovascular diseases, (3) individual age equal or
greater than 18 years, and (4) body mass index (BMI) in a
physiological range (16–35) [1]. In all cases, subjects provid-
ed informed consent.
Models Development Methodology
The aim of this section is to describe the steps undertaken to
create a regression model of the relationship between the
LVPWd and age, BSA and sex. BSAwas calculated according
to the widely accepted approximation BSA≅0.20247 ⋅
Height (m)0.725⋅Weight (kg)0.425 [21]. As previously noted,
according to the medical diagnostic guidelines, the LVPWd in
healthy humans takes on values in the interval 6–11 mm. Due
to this restriction, we decided to model the distribution of the
LVPWd as a continuous limited random variable. The current
state of knowledge in the area of modeling this kind of
variables suggests that the preferred approach is the so-
called 'beta regression'. The following exposition of 'beta
regression' follows closely the Cribari-Neto and Zeileis study
[22].
The usual practice while performing a regression analysis
in which the dependent variable (response variable, y) takes
on values in the interval (a, b) (with a < b known) is to
completely ignore this fact and perform an ordinary regression
analysis as if the dependent variable assumed values in the real
line. This approach, nonetheless, has many limitations. The
most important one in the context of this study is that the
simulations from a model not respecting the natural limits of
the dependent variable may generate values outside the (a, b)
limits. Better yet, although it is still not optimal, in this
approach we first use the linear transformation y = (y − a)/(b
− a) (in the case considered in this article a = 6 and b = 11),
after which y assumes values from 0 to 1. The next step is to
logit-transform the data so that the transformed response
assumes values in the real line, and then to apply a standard
linear regression analysis. This approach, however, suffers
from other limitations. First, regressions involving data from
the finite interval are typically heteroscedastic, i.e., they dis-
play more variation around the mean, and less variation
around the lower and upper limits of the interval. Second,
the distribution of limited variable is typically asymmetric,
and thus Gaussian-based approximation for estimation, hy-
pothesis testing and simulation can be inaccurate. Ferrari and
Cribari-Neto [23] proposed a regression model for continuous
variable that assumes values in the standard unit interval.
Since the model is based on the assumption that the response
is beta-distributed, they called their model the beta regression
model. The model is naturally heteroscedastic and easily
accommodates asymmetries. A generalization of the beta
regression model was proposed by Simas et al. [24]. In this
model, the parameter accounting for the precision of the data
is not assumed to be constant across observations but it is
allowed to vary, leading to the variable dispersion beta regres-
sionmodel (VDBRM). The VDBRMmodel will be employed
in our analysis of the LVPWd.
Table 1 Summary of the physiological parameters used for the simula-
tion study
Parameter Unit Mean (SD)
Plasma potassium concentration mM 4.29 (0.28)
Plasma sodium concentration mM 139.37 (1.26)
Plasma calcium concentration mM 2.36 (0.18)
Cardiomyocyte volume μm3 7254.90 (4912.68)
Stimulation period ms 909.37 (136.20)
Electric capacitance pF 55.16 (32.91)
All parameters derived randomly from the models (references to the
models used for deriving the above listed values can be found in the text
[17–19]) describing parameter distribution in the population of healthy
individuals (60 virtual individuals)
Table 2 Characteristics of the clinical and echocardiographic data used
for the modeling purposes
UHZ data set Polish data set
Sample size Males 2,104 189
Females 2,368 128
Age (years) Males 42.1 (13.2, 18.0–79.8) 36.6 (13.6; 18–75)
Females 42.9 (13.1, 18.0–78.4) 42.3 (14.1; 18–71)
BSA (m2) Males 1.95 (0.17, 1.34–2.73) 2.0 (0.16; 1.53–2.44)
Females 1.69 (0.15, 1.28–2.34) 1.69 (0.13; 1.44–2.04)
BMI (kg/m2) Males 24.7 (3.4, 16.2–35.0) 26.1 (3.4; 18.4–34.3)
Females 23.3 (3.9, 16.1–34.8) 24.3 (3.9; 17.0–34.4)
LVPWd (mm) Males 8.76 (1.04, 6.1–10.9) 9.55 (0.97; 7–10.94)
Females 7.78 (0.98, 6.1–10.9) 8.63 (1.22; 6.1–10.9)
Values presented as mean (standard deviation, minimum – maximum)
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The VDBRM is based on an alternative parameterization of
the beta density in terms of the mean (μ) and precision
parameter (ϕ):
f y;μ;ϕð Þ ¼ Γ μð Þ
Γ μϕð ÞΓ 1−μð Þϕð Þy
μϕ−1 1−yð Þ 1−μð Þϕ−1
with y∈(0,1), μ∈(0,1) and ϕ>0. Let y1,y2,…,yn be a sample
of independent data-points such that yi has f (yi;μi,ϕi) distribu-
tion. The VDBRM is defined as:
g1 μið Þ ¼ β0 þ x1iβ1 þ…þ xkiβk
g2 ϕið Þ ¼ γ0 þ z1iγ1 þ…þ zpiγp ;
where g1 and g2 are logistic and logarithmic link functions, x
and z are independent variables (covariates), β and γ are
unknown regression parameters.
In this study, model parameters were estimated by the
method of bias-reduced maximum likelihood as implemented
in the betareg package in the R system for statistical comput-
ing [22]. A model fit was described using the coefficient of
pseudo-determination R2. Model adequacy was assessed
using different types of diagnostic plots: residuals vs. indices
of observations, Cook’s distance plot, generalized leverage vs.
predicted values, residuals vs. linear predictor, half-normal
plot of residuals, predicted vs. observed values.
In search of the most parsimonious model specification we
employed the backward stepwise strategy. The starting
models included linear effects of quantitative variables, dum-
my sex variable (1 = male) and pairwise interaction terms. All
mentioned terms were included in both mean and precision
model equations. The elimination of predictors was guided by
the likelihood ratio test. The modeling exercise was separately
performed on Polish and UHZ data
In addition to regression modeling, a tool for simulation of
random individual LVPWd, given values of independent var-
iables from estimated models is provided. The tool takes form
of an Excel spreadsheet (electronic supplement) that uses
built-in standard beta cumulative distribution function. The
necessary translation between reparameterized and standard
beta distribution is described in detail by Ferrari and Cribari-
Neto [23].
Electrocardiogram (ECG) Simulation Methodology
The LVPWd was used as a surrogate of the left heart wall
thickness and it was hypothesized that by modifying the
length of the string of virtual cells according to the developed
LVPWd models one can influence the electrophysiological
model outputs and therefore more reliably predict the clinical-
ly expected inter-individual variability [25]. Two BDMM’s
outputs were simulated and both of them were derived from
the simulated pseudo-ECG traces, i.e., QT and QT corrected
by the heart rate with the Fridericia equation (QTcF). The
computer simulations were designed and carried out using
the Cardiac Safety Simulator (CSS platform). It is worth
mentioning that every element of the system including phys-
iological parameters and their variability was described in a
form of a scientific publications with all necessary algorithms
included. For details regarding the CSS and abovementioned
publications see certara.com, tox-portal.net and citations enu-
merated in this section. The ten Tusscher model of the human
left ventricular cardiomyocyte built-in to the CSS and utilized
for the current study is considered to be one of the state-of-the-
art models in its field [26]. The Forward Euler method was
employed to integrate model equations. A one-dimensional
fiber of cardiomyocytes comprised of 50% endocardial, 30%
midmyocardial and 20% epicardial cells was constructed for
each simulated virtual individual. All other physiological pa-
rameters descr ib ing vir tual individuals , namely
Table 3 Parameter estimates, 95% confidence intervals (CI) and p values
Submodel Predictor Parameter Polish data UHZ data
Point estimate 95% CI p value Point estimate 95% CI p value
Mean submodel Intercept β0 −1.428 (−1.890 to −0.965) 0.000 −1.176 (−1.269 to −1.083) 0.000
Age β1 0.034 (0.023 to 0.045) 0.000 0.013 (0.011 to 0.015) 0.000
Sex β2 2.169 (1.558 to 2.780) 0.000 0.851 (0.799 to 0.903) 0.000
Age and sex interaction β3 −0.029 (−0.044 to −0.014) 0.000 – –
Precision submodel Intercept γ0 2.696 (1.937 to 3.454) 0.000 1.432 (1.394 to 1.470) 0.000
Age γ1 −0.030 (−0.046 to −0.014) 0.000 – –
Sex γ2 −1.382 (−2.315 to −0.449) 0.004 – –
Age and sex interaction γ3 0.032 (0.011 to 0.053) 0.003 – –
Presented data describe model with age and sex as predictors which were further used for the simulation study
β, γ are regression parameters (please see the text for further details)
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cardiomyocytes morphometric parameters (volume, area,
electric capacitance), plasma ions concentration (K+, Na+,
Ca2+) and heart rate were specific for healthy individuals,
and CSS default parameters for the empirical models describ-
ing inter-individual variability in population were utilized (see
summary in Table 1). All virtual individual’s physiological
parameters were kept constant across simulated scenarios in
order to remove unwanted heterogeneity that might otherwise
obscure observation of the LVPWd impact on the simulated
endpoints. Simulations were carried out for 60 virtual individ-
uals (30 males, 30 females). All of them were wild type ionic
channels genetic variant carriers.
Three simulation scenarios were evaluated. In the first
scenario, the string length was set to a constant value calcu-
lated as the average of all available LVPWd data (8.3 mm). In
the second scenario, the LVPWd was randomly drawn from
the Sjögren model whose shortcomings were described in the
Introduction. However, this model is currently available as an
option in the CSS platform and for this reason such a scenario
has been included. In the third scenario, the LVPWd was
randomly drawn from the age–sex LVPWd model developed
on Polish data (abbreviated as ASLPM). Among all the
models developed in this study, this one seemed to be of the
highest practical relevance. Each scenario included two
Fig. 1 Relationship between LVPWd and age calculated with use of the developed models. a Polish data, bUHZ data. The bold curves from the bottom
to top describe 5th, 25th, 50th, 75th and 95th conditional percentiles of the LVPWd, respectively
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subscenarios – with and without the test drug (disopyramide),
which was assumed to inhibit IKr ionic current in the concen-
tration dependent manner. The Hill equation parameters pro-
vided as the input data for CSS were 9.64 μM and 1 for the
IC50 and N, respectively, which resulted in 62% of the IKr
current inhibition for the tested active concentration (15 μM)
[27]. Distinction between drug/no drug scenarios allows us to
evaluate the impact of the LVPWd under markedly different,
yet clinically important, situations since BDMMs are increas-
ingly used as a tool for early drug safety assessment [28–31,
34, 35].
Results
Modeling Results
In Table 2, sample sizes along with basic descriptive charac-
teristics (mean, standard deviation, minimum − maximum) of
the collected data are presented.
Estimation results of the first model are reported in
Table 3, separately for Polish and UHZ datasets. In this
model, only age and sex were allowed to enter model
equations. Model coefficients in the mean submodel are
interpretable in terms of the mean of scaled and logit
transformed LVPWd, and not in terms of the mean of
the original LVPWd. Consequently, we aid our interpre-
tation by plotting model results. Figure 1 shows the
estimated relationship between LVPWd and both age
and sex, also separately for Polish and UHZ datasets.
Since the LVPWd is a limited variable, as mentioned
before, the y-axis is constrained to the interval from 6
to 11 mm.
In the case of Polish data, the estimates of sex effect and
age slopes were statistically significant. Also, interaction
terms were statistically significant, meaning that age slopes
are inferred to be different between males and females. The
coefficient of pseudo-determination R2=0.19. Figure 1a
shows the interaction between age and sex in both mean and
precision. In males, one can notice a very weak positive effect
of age on the LVPWd and a weak negative age effect on
dispersion of the LVPWd. In females, the effect of age on
the LVPWd is much stronger and there is a positive age effect
on dispersion of the LVPWd. The male median LVPWd
increases from 9.67 to 9.82 mm, the female median LVPWd
increases from 7.5 to about 8.9 mm, when age is varied from
20 to 50.
In the case of UHZ data, sex and age effect estimates on the
LVPWd were statistically significant. The differences between
males and females were present on the overall LVPWd level
(Fig. 1b). In comparison to the Polish model, interaction terms
between age and sex were not statistically significant; also
there was no evidence that the dispersion of LVPWd is age- or
sex-dependent. Consequently, the structure of the UHZ model
is much simpler than that of its Polish counterpart. The coef-
ficient of pseudo-determination R2=0.19. The male median
LVPWd increases from 8.4 to 9.0 mm, the female median
LVPWd increases from 7.3 to about 7.8 mm, when age is
varied from 20 to 50.
Estimation results of the second model are reported
in Table 4. In this model, only BSA and sex were
allowed to enter model equations, age was excluded.
Figure 2 shows the estimated relationship between the
LVPWd and both BSA and sex, separately for Polish
and UHZ datasets. In the case of Polish data, it was
found that in the presence of BSA, sex and interaction
between sex and BSA were not significant, in both
mean and precision equations, meaning that the esti-
mated relationship between BSA and LVPWd is the
same in males and females . The coeff ic ient of
pseudo-determination R2=0.17, which is noticeably
smaller than in the first model. Figure 2a shows a
strong positive effect of BSA on LVPWd and a strong
negative BSA effect on the dispersion of the LVPWd.
Table 4 Parameter estimates, 95% confidence intervals (CI) and p values— model with BSA and sex as predictors
Submodel Predictor Parameter Polish data UHZ data
Point estimate 95% CI p value Point estimate 95% CI p value
Mean submodel Intercept β0 −3.372 (−4.332 to −2.413) 0.000 −3.201 (−3.480 to −2.923) 0.000
BSAβ1 β1 2.128 (1.619 to 2.638) 0.000 1.534 (1.371 to 1.697) 0.000
Sex β2 – – 0.452 (0.387 to 0.517) 0.000
BSA and sex interaction β3 – – – –
Precision submodel Interceptγ0 γ0 −0.218 (−1.481 to 1.046) 0.736 1.469 (1.431 to 1.507) 0.000
BSA γ1 0.824 (0.147 to 1.500) 0.017 – –
Sex γ2 – – – –
BSA and sex interaction γ3 – – – –
β, γ are regression parameters (please see the text for further details)
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Median LVPWd increases nonlinearly from 8.2 to
about 10.1 mm for BSA increasing from 1.5 to 2.2 m2.
In the case of the UHZ data, the mean submodel includes
both BSA and sex, but not the interaction between them.
There was no evidence that the dispersion of LVPWd is
BSA- or sex-dependent. The coefficient of pseudo-
determination R2=0.22, which is higher than in the first mod-
el. Figure 2b shows a strong positive effect of BSA on
LVPWd and level differences between males and females.
The male median LVPWd increases from 7.9 to 9.4 mm, the
female median LVPWd increases from 7.3 to about 8.8 mm,
when BSA is varied from 1.5 to 2.2.
Simulation Results
Simulation results are presented in Table 5 and depicted in
Fig. 3, separately for three tested scenarios. In the case of QT
measurements, either with or without the presence of the
tested drug, it can be noted that Scenario 2 (Sjögren model)
resulted in a higher average QT as compared to the other two
scenarios. Also, the use of the LVPWd models (Scenarios 2
and 3) resulted in a larger variability of QTas compared to the
constant value scenario. However, the differences in variabil-
ity between scenarios were almost nullified when the QTwas
corrected by the heart rate with the Fridericia equation. The
Fig. 2 Relationship between LVPWd and BSA calculated with use of the developed models. a Polish data, b UHZ data. The bold curves from the
bottom to top describe 5th, 25th, 50th, 75th and 95th conditional percentiles of the LVPWd, respectively
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differences in average QT levels between scenarios did not
change after correction.
Discussion
The current study was preceded by an introductory data search
study. The available scientific literature databases (Medline,
Google Scholar, Scopus) were queried for publications de-
scribing the LVPWd in healthy individuals that were neither
professional nor recreational athletes. The individuals were to
be free of pathological cardiovascular changes, not carrying
congenital heart pathologies and not taking any drugs related
to cardiovascular disorders. Whenever possible, in addition to
the LVPWd data, the age, gender, height, weight, BSA and
BMI were collected. In total, 132 publications containing any
relevant data were retrieved. The majority of publications was
not primarily concerned with the LVPWd and consequently
provided only aggregated data, i.e., mean and standard devi-
ations, only a handful of publications provided a small number
of individual data. After initial experimentation, it was found
that the utilization of heterogeneous aggregate literature data
to develop reliable LVPWd models poses a very challenging
task. Therefore, it was decided to seek another source of
information and perform modeling solely on individual data.
Two separate variable dispersion beta regression models
(VDBRM) were developed, where age and gender as well as
BSA and gender were shown to be statistically significant
parameters describing the LVPWd. The LVPWd models were
developed separately for the Polish and UHZ data sets. The
main reason for this distinction was that we could envision a
situation in which a cross-country comparison might be of
interest to a reader as we had observed statistically significant
differences between samples obtained from two countries (on
Table 5 Results of the BDMM-based simulations with use of the CSS system for various string length values (constant, Sjögren model derived and
newly developed ASLPM model derived)
Simulation end-point Scenario 1 (constant value) Scenario 2 (Sjögren model) Scenario 3 (ASLPM model)
All Female Male All Female Male All Female Male
String of cells length (mm) mean 8.3 8.3 8.3 13.0 13.0 13.1 8.8 8.1 9.5
SD 0 0 0 2.0 1.8 2.1 1.3 1.1 1.2
QT baseline — no drug (ms) mean 345.7 344.4 346.9 352.8 351.6 354.0 346.1 343.6 348.7
SD 3.7 2.0 4.5 4.2 3.2 4.8 4.8 3.2 4.8
QT — with drug (ms) mean 377.0 376.1 377.8 384.8 384.0 385.6 377.4 375.1 379.8
SD 2.8 1.9 3.2 3.8 3.5 3.9 4.2 3.2 3.7
QTcF baseline — no drug (ms) mean 358.3 359.1 357.4 365.7 366.7 364.7 358.8 358.3 359.2
SD 15.7 15.8 15.5 16.7 17.0 16.2 16.2 16.7 15.7
QTcF— with drug (ms) mean 390.7 392.2 389.3 398.9 400.4 397.4 391.2 391.1 391.3
SD 17.4 17.6 17.1 18.6 19.0 18.0 18.0 18.6 17.4
ΔQTcF (ms) mean 32.5 33.1 31.9 33.2 33.8 32.6 32.5 33.1 31.9
SD 2.6 2.6 2.4 2.8 2.8 2.6 2.6 2.6 2.4
Baseline QTcF Drug QTcF ΔQTcF
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Fig. 3 Simulated QTcF (a baseline, b with drug) andΔQTcF values for
three tested scenarios. Diamond, circle and triangle represent three tested
scenarios— average value, current model predictions, and Sjögren model
predictions of the LVPWd, respectively (empty, shaded and filled symbols
represent women, men and all individuals, respectively)
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average, 8.76 vs. 9.57 mm for males and 7.78 vs. 8.65 mm for
females for Swiss and Polish data, respectively). Additionally,
since the UHZ data set is more than 15 times larger than the
Polish data set, it was clear that the models developed on the
merged data set would be practically no different from the
models developed on only the UHZ data set (results not
presented), effectively hiding between-country differences.
The modelling indicated that, in the case of Polish data, the
male median LVPWd increases from 9.6 to 10.0 mm, and the
female median LVPWd increases from 7.4 to about 9.3 mm,
while in the case of UHZ data, the male median LVPWd
increases from 8.4 to 9.0 mm, and the female median LVPWd
increases from 7.3 to about 7.8 mm, in function of age (20–50
years). However, the cause of these phenomena is not clear
and it is equally likely that it might be a result of differences in
the studied population as well as being operator-dependent.
Model including all three predictors namely age, gender, and
BSA was also considered, however in terms of R2 it was no
better than any of the bivariate models. The most important
from the practical point of view is the model with age and
gender as predictors since, for example, the distribution of
both can be anticipated during the planning of a clinical trial
thereby allowing the use of the BDM model in the clinical
trials simulations. The BSA distribution among the clinical
trial’s participants is less practical in use and possibly biased
by the need of approximation. Consequently the models in-
corporating BSA (gender, BSA or gender, age, BSA) were
deemed less relevant. However, as the relation between BSA
and various measurement of heart structure is a frequent
subject in the literature, such models were also presented.
As shown in this study, themodels of the LVPWd can serve
not only a descriptive purpose but can also be used to include
inter-human differences in physiology into biophysically de-
tailed mathematical models describing the electrophysiology
of the human left ventricular heart wall. To test the sensitivity
of the BDMMcaused by the inclusion of the models of human
LVPWd covering the physiological range of values, three
competing approaches were investigated (Sjögren model and
average LVPWd value against one of the newly established
models). As it was presented in the 'Simulation results' sec-
tion, the mean of ΔQTcF and its variability is comparable
across all scenarios, leading to the conclusion that on the
aggregate level, the inclusion of the LVPWd models does
not change this important outcome. However, a closer look
at the individual simulation results leads to a different conclu-
sion, i.e., the inclusion of the models induces a positive
correlation between the LVPWd and simulation outcomes,
which brings them closer to reality by dismissing the previ-
ously made assumption of independence between LVPWd
and electrophysiological outcomes. The LVPWd and the
QTc correlation is close to linear; however, the ΔQTcF does
not follow such a simple relation — this correlation is mod-
erately nonlinear (result not shown). Differences between
genders partially depend on the LVPWd model, although
other BDMM’s parameters— e.g., main plasma ions concen-
trations, cardiomyocyte volume — also play a role. The
physiological range of the QT is wide, spanning the range of
300–450 ms, dependent on age, gender, heart rate and other
parameters [32–34]. Detailed analysis of such phenomenon
would require a separate, thoroughly planned and conducted
numerical experiment. Therefore, based on the simulated QT
values it is not possible to particularly recommend any of the
developed models as all of them meet the criteria specific for
healthy individuals. There is, however, one element that
should be taken into consideration when using biophysically
detailed models of the cardiomyocytes for the drug safety
assessment needs. Since they are planned to be used at an
early stage of drug safety assessment as tools integrating
in vitro studies results (drug-triggered ionic currents
inhibition), their role is to mimic mainly healthy individuals
[10]. In this case, currently proposed models would be rec-
ommended in opposition to the Sjögrenmodel whose LVPWd
predictions fall strongly above the current normal limits.
One of the limitations of the study is the assumption that
the length of the cell string equals the heart wall thickness. In
addition, the posterior location was assumed to be a place
where the simulated electrophysiological phenomenon oc-
curs. It is a clear oversimplification of the very complex
physiological process. It is believed, however, to be adequate
enough to be practically useful. Other limitation is connected
with the unidimensionality (1D) of the employed BDMM. A
3Dmodel of the heart, ideally with its geometry obtained with
use of the MRI data, is necessary to compute physiological
ECG, which in the current study was approximated by a
surrogate, pseudo-ECG from 1D model [35, 36]. Such sim-
plification was dictated mainly by the high computational cost
of 3D approach which would render its practical large-scale
application disputable.
Conclusions
Physiological parameters influence the clinically observed
drug-triggered ECG disruption and reactivity on drugs [25].
Therefore, the development of physiological parameters
models, estimated with the use of rich, multicenter clinical
data, can help to properly mimic populations involved in the
clinical trials. Such new models, quantifying the relation
between the LVPWd and the basic demographic and physio-
logical parameters, were established and their performances
were verified. Their usefulness was tested during the in silico
study, where a model describing the left ventricular human
cardiomyocyte electrophysiology was used for the electro-
physiological endpoints simulation. As a result, the developed
LVPWd models could be used in the in silico assessment of
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